Several studies have compared the results of unrelated donor bone marrow transplantation (UBMT)
and unrelated donor cord blood transplantation (UCBT). To objectively analyze …

Tyrosine kinase inhibitors (TKIs) elicit high response rates among individuals with kinase-driven
malignancies, including chronic myeloid leukemia (CML) and epidermal growth factor …

This article has been corrected. The original version (PDF) is appended to this article as a
Supplement . Background: Invasive aspergillosis (IA) is associated with poor outcomes in …

The successful expansion of hematopoietic stem and progenitor cells (HSPCs) from umbilical
cord blood (UCB) for transplantation could revolutionize clinical practice by improving …

Background Voriconazole has been recommended as primary treatment for patients with
invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have improved …

Purpose Allogeneic transplantation is typically limited to younger patients having a matched
donor. To allow a donor to be found for nearly all patients, we have used a …

Omidubicel is an ex vivo expanded hematopoietic progenitor cell and nonexpanded myeloid
and lymphoid cell product derived from a single umbilical cord blood unit. We report results …

Purpose Increasing the number of hematopoietic stem and progenitor cells within an
umbilical cord blood (UCB) graft shortens the time to hematopoietic recovery after UCB …

The epidemiology of human fungal infections has evolved considerably over the past 3
decades, mainly due to the rising prevalence of immunocompromised patients worldwide …

Fedratinib, an oral Janus kinase‐2 (JAK2) inhibitor, reduces splenomegaly and improves
symptom burden in patients with myelofibrosis. Regulatory approval of fedratinib 400‐mg daily …